[go: up one dir, main page]

CA2169735A1 - Compositions orales d'antagonistes de h2 - Google Patents

Compositions orales d'antagonistes de h2

Info

Publication number
CA2169735A1
CA2169735A1 CA 2169735 CA2169735A CA2169735A1 CA 2169735 A1 CA2169735 A1 CA 2169735A1 CA 2169735 CA2169735 CA 2169735 CA 2169735 A CA2169735 A CA 2169735A CA 2169735 A1 CA2169735 A1 CA 2169735A1
Authority
CA
Canada
Prior art keywords
composition
calcium carbonate
antagonist
weight
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2169735
Other languages
English (en)
Inventor
Henry C. Caldwell
Ashok J. Desai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AAIPharma Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2169735A1 publication Critical patent/CA2169735A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Comprimés à mâcher d'antagonistes de H2 qui n'ont pas de goût dans la bouche, mais permettent une bonne libération des ingrédients actifs. Lesdits comprimés sont préparés à l'aide de carbonate de calcium et d'un silicate de magnésium-aluminium en tant que support. Ils contiennent également des ingrédients non essentiels tels que du xylitol et des acides de fruits.
CA 2169735 1993-08-17 1994-08-16 Compositions orales d'antagonistes de h2 Abandoned CA2169735A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10712693A 1993-08-17 1993-08-17
US28871194A 1994-08-12 1994-08-12
US08/288,711 1994-08-12
US08/107,126 1994-08-12

Publications (1)

Publication Number Publication Date
CA2169735A1 true CA2169735A1 (fr) 1995-02-23

Family

ID=26804421

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2169735 Abandoned CA2169735A1 (fr) 1993-08-17 1994-08-16 Compositions orales d'antagonistes de h2

Country Status (5)

Country Link
EP (1) EP0715516A1 (fr)
JP (1) JPH09501680A (fr)
AU (1) AU7565594A (fr)
CA (1) CA2169735A1 (fr)
WO (1) WO1995005173A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622980A (en) * 1993-08-17 1997-04-22 Applied Analytical Industries, Inc. Oral compositions of H2-antagonists
US6537525B1 (en) * 1997-01-29 2003-03-25 Douglas H. West Medicated chewing-gum
DE10200405A1 (de) 2002-01-08 2002-08-01 Zimmer Ag Spinnvorrichtung und -verfahren mit Kühlbeblasung
DE10204381A1 (de) 2002-01-28 2003-08-07 Zimmer Ag Ergonomische Spinnanlage
DE10206089A1 (de) 2002-02-13 2002-08-14 Zimmer Ag Bersteinsatz
WO2007108010A2 (fr) * 2006-03-21 2007-09-27 Jubilant Organosys Limited Composition pharmaceutique à goût masque pour forme dosifiée orale solide et son procédé de préparation
HUE067442T2 (hu) 2017-11-09 2024-10-28 Convatec Technologies Inc Sztómafigyelõ rendszer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992017164A1 (fr) * 1991-04-04 1992-10-15 The Procter & Gamble Company Compositions pharmaceutiques administrees par voie buccale dans le traitement de troubles de la partie superieure des voies gastro-intestinales
US5229137A (en) * 1992-05-06 1993-07-20 Brigham And Women's Hospital, Inc. Methods and pharmaceutical compositions for treating episodic heartburn

Also Published As

Publication number Publication date
AU7565594A (en) 1995-03-14
WO1995005173A1 (fr) 1995-02-23
EP0715516A1 (fr) 1996-06-12
JPH09501680A (ja) 1997-02-18

Similar Documents

Publication Publication Date Title
AU681672B2 (en) Preparations containing silicon dioxide to improve the taste thereof
US5225197A (en) Pharmaceutical formulation
CA2311734C (fr) Forme pharmaceutique orale a dissolution ultra-rapide
JP2918691B2 (ja) ラニチジン組成物
HK1004522B (en) Pharmaceutical formulation
US20030083354A1 (en) Phenylephrine tannate and pyrilamine tannate salts in pharmaceutical compositions
US5814339A (en) Film coated tablet of paracetamol and domperidone
HRP20030527A2 (en) Pharmaceutical compositions comprising amlodipinemaleate
US5468504A (en) Effervescent pharmaceutical compositions
US5622980A (en) Oral compositions of H2-antagonists
CA2169735A1 (fr) Compositions orales d'antagonistes de h2
JP3587869B2 (ja) 医薬組成物
WO1996004888A1 (fr) Compositions d'antagonistes h2 s'administrant par voie orale
US20040132827A1 (en) Phenylephrine tannate, pyrilamine tannate and dextromethorphan tannate salts in pharmaceutical compositions
WO1996019220A1 (fr) Produit composite comprenant de la nitazoxanide et un agent antiulcereux
SK19192000A3 (sk) Použitie paroxetínu alebo jeho farmaceuticky prijateľnej soli alebo solvátu na podporu odvykania od fajčenia alebo na zníženie alebo prevenciu relapsu fajčenia
CN1140996A (zh) 雷尼替丁和碳酸钙药物复合品
HK1074009A (en) Flash-melt oral dosage formulation
EP0574624A1 (fr) Compositions pharmaceutiques
HK1010687B (en) Film coated tablet of paracetamol and domperidone

Legal Events

Date Code Title Description
FZDE Dead